Recently, it was shown that this can be accomplished in CD4+ T cells with the use of dasatinib, a Bcr-Abl-specific TKI that has been approved for use in chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ AML) by the FDA (29, 30). This evidence concerns the gene CD4 and chronic myelogenous leukemia, BCR-ABL1 positive.